NCT05380024Unknown2 期
A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer
Peking University Cancer Hospital & Institute2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2022年8月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Major Pathological Response (MPR)
研究概览
简要总结
This is a Phase II, single-Arm, prospective study of neoadjuvant Ensartinib for the treatment of patients with ALK positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- •Male or female, at least 18 years of age.
- •Histologically or cytologically documented lung adenocarcinoma within 60 days prior to study enrollment.
- •Clinical stage IIA/IIB/IIIA/IIIB assessed by EBUS-TBNA or PET(positron emission tomography)/CT can be resected.
- •Patients confirmed as ALK positive (FISH or Ventana IHC or RT-PCR, NGS)
- •Presence of at least one accurately measurable lesion, CT showing a maximum diameter of 10mm at baseline (except for lymph nodes with a short axis of 15mm required) and suitable for accurate repeat measurements.
- •Eastern Cooperative Oncology Group (ECOG) performance status （PS） of 0 or 1 at enrolment.
- •Hematology , liver and kidney function are adequate for neoadjuvant therapy.
- •Cardiopulmonary function suitable for surgical treatment (ECG, echocardiography, pulmonary function or blood gas analysis).
- •Serum pregnancy test (for females of childbearing potential) negative at screening.Female patients of non-childbearing potential must meet at least 1 of the following criteria:
- •① Achieved postmenopausal status, defined as follows: cessation of regular menses forat least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle- stimulating hormone (FSH)level confirming the postmenopausal state;
- •② Have undergone a documented hysterectomy and/or bilateral oophorectomy;
- •③ Have medically confirmed ovarian failure. All other female patients (including female patients with tubal ligations） are considered to be of childbearing potential.
- •Male subjects must be willing to use barrier contraception
排除标准
- •Mixed squamous cell carcinoma, large cell carcinoma，small cell lung cancer.
- •Prior treatment with any systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug.
- •Pregnant female patients; breastfeeding female patients.
- •Current use of (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of Cytochrome P450 3A4(CYP3A4)(at least 3 weeks prior).
- •Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding, that the investigator considers to be detrimental to patient participation in the study or to adherence to the protocol. Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV) or hepatitis C virus (HCV) (e.g., in case of known HBsAg or HCV antibody positivity), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness.
- •Past medical history of Interstitial lung disease（ ILD）, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
- •A history of hypersensitivity to Icotinib with or without active excipients or to drugs of similar chemical structure or class, and uncontrollable nausea and vomiting, chronic gastrointestinal disease, inability to swallow formulated drugs, or having undergone major bowel resection that would interfere with adequate absorption of Ensartinib.
- •Any of the following cardiac criteria:
- •①Mean resting corrected QT interval (QTc)>470 msec, obtained from 3 electrocardiograms (ECGs)
- •②Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval >250msec, symptomatic bradycardia <45 beats/minute.
- •③Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval.
- •A clear past history of neurological or psychiatric disorders, including epilepsy or dementia;
- •Judgment by the investigator that the subject should not participate in the study if the subject is unlikely to comply with study procedures, restrictions and requirements.
研究组 & 干预措施
Ensaritinib
Experimental
干预措施: Ensartinib (Drug)
结局指标
主要结局
Major Pathological Response (MPR)
时间窗: From date of randomization to an average of 12 weeks after the first dose
Defined as ≤10% residual cancer cells in the main tumour, as assessed per central pathology laboratory post-surgery
次要结局
- Pathological complete response (pCR)(From date of randomization to an average of 12 weeks after the first dose)
- Incidence of Adverse Events(From the time of enrollment to either 28-days after the last dose of last study treatment for patients who do not undergo surgery, or 90-days post-surgery)
- Objective response rate(ORR)(Baseline (Prior to surgery))
- Disease free survival (DFS)(From date of randomization up to approximately 42 months after date of resection)
- Overall Survival (OS）(Up to approximately 5.5 years after the last patient is randomized)
研究者
Wu Nan
Clinical Professor
Peking University Cancer Hospital & Institute
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung CancerNon-small Cell Lung CancerNCT05241028Hebei Medical University Fourth Hospital80
进行中（未招募）
2 期
Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 MutationNon-Small Cell Lung CancerNCT05491811Sun Yat-sen University47
尚未招募
2 期
The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk FactorsALKStage IAdjuvant TreatmentNSCLCNCT06772610Shanghai Pulmonary Hospital, Shanghai, China40
终止
2 期
Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung CancerStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerNCT01857271Albert Einstein College of Medicine3
尚未招募
不适用
Pyrotinib in HER2-positive Early Breast CancerHER2-positive Breast CancerNCT06718335Nie Jianyun156